REGENXBIO 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Regenxbio ended the 3rd quarter of 2026 with $251 million in cash, cash equivalents, and marketable securities, compared to $241 million as of December 31st, 2025.
- The increase included a $100 million milestone payment from AbbVie in July 2026 for dosing the first patient in the Phase 2b/3 NAVIGATE study and net proceeds of $108 million from an underwritten public offering completed in July 2026.
- The cash balance excludes a $49 million payment received in October 2026 pursuant to a settlement agreement with Soropta Therapeutics.
- Regenxbio continues to receive Zolgensma royalties in select OUS territories and Efesma royalties in the U.S. and certain OUS territories.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, everyone, to the third quarter 2026 Regenxbio earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I will now turn the conference over to Patrick Christmas, Chief Legal Officer of Regenxbio.
Please go ahead. Good morning, and thank you for joining us today.
Earlier this morning, Regenxbio released financial and operating results for the third quarter ended September 30, 2026. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted, and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties.
These risks are described in the risk factors and the management's discussion and analysis section of Regenxbio's annual report on Form 10-K for the full year ended December 31, 2025, and comparable risk factor sections of Regenxbio's quarterly report on Form 10-Q, which will be on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, November 5, 2026, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events, or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.
I'll now turn the call to Curran Simpson, President and CEO of Regenxbio.
Curran? Thank you, Patrick, and good morning, everyone.
Thank you for joining us today. This is an exciting time for REGENXBIO. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pakola, our Chief Medical Officer, and Mitch Chan, our Chief Financial Officer. I will provide an update on our lead programs before turning it over to them for additional details. I will begin with sura-vec, our potential first-in-class gene therapy for wet AMD and diabetic retinopathy, developed in collaboration with AbbVie. Ahead of our top-line pivotal readout expected later this year, last month, we hosted an investor event featuring five leading retina specialists. They discussed the opportunity for sura-vec to transform the wet AMD treatment paradigm. I want to highlight three key takeaways from the event. First, the unmet need in wet AMD remains significant.
While anti-VEGF therapies are highly effective, the burden of frequent injections can be difficult for patients to sustain over time. As a result, patients who are unable to maintain consistent treatment schedules may not realize the full potential benefit of today's standard of care and subsequently lose vision. Second, sura-vec has the potential to benefit a broad spectrum of patients, including those with high disease activity and those with bilateral disease. During our event, the physicians reinforced the advantages of a one-time treatment across the range of wet AMD patients they treat and pointed to patients with high disease burden as ideal candidates for gene therapy. We and AbbVie incorporated these patients in our clinical studies, giving us a potential advantage in obtaining a broad label and treating these patients commercially. sura-vec pivotal studies include a broad population of patients, including newly diagnosed and treatment-experienced patients.
Additionally, sura-vec is the only late-stage gene therapy program with reported clinical data supporting treatment in both eyes. Third, sura-vec is well-positioned for commercial adoption. The commercial infrastructure for subretinal delivery already exists due to Luxturna and other approved therapies. Further, we know the majority of retina specialists performing these procedures are at high-volume centers, many of whom are included in our pivotal studies. We and AbbVie have already laid a significant foundation, having trained over 500 retina specialists to date. Together, these factors, combined with AbbVie's global reach and leading eye care capabilities, give us confidence as we proceed towards potential commercial launch. We expect top-line results from both ATMOSPHERE and ASCENT this quarter, followed by global regulatory submissions in 2027. Looking ahead, we see wet AMD as the tip of the spear in terms of transforming the treatment paradigm for chronic retinal diseases.
We are currently enrolling in the phase IIb/III NAAVIGATE study in diabetic retinopathy. Current anti-VEGF therapy is vastly underused in DR due to the treatment burden for patients, who are predominantly middle-aged working adults. We believe a one-time gene therapy has the potential to address this large unmet need and represents another potential blockbuster opportunity for sura-vec. Turning to RGX-202, we continue to make meaningful progress towards bringing our potential best-in-class gene therapy for Duchenne to patients in the U.S. and beyond. Preparations are well underway to submit the BLA under the accelerated approval pathway in the first quarter of 2027, supporting potential approval in the U.S. in the second half of 2027. As a reminder, the BLA is expected to include data from both our pivotal and confirmatory studies.
Outside of the U.S., momentum for RGX-202 continues, and we remain on track to initiate our ex-U.S. randomized placebo-controlled study named AFFINITY® RISE in the first half of 2027. We continue to be highly encouraged by the impressive microdystrophin, functional, and safety data to date, which demonstrate the potential of RGX-202 to meaningfully improve outcomes for patients with Duchenne. We have strong support from treating physicians, families, and advocacy organizations. At our FDA-inspected in-house manufacturing innovation center, we continue to manufacture intended commercial supply in anticipation of a potential 2027 commercial launch. We are sharply focused on advancing our late-stage pipeline, executing against upcoming milestones, and making disciplined investment decisions that support these priorities. With that, I'll turn it over to Steve.
Thank you, Curran, and good morning, everyone. I'll begin by speaking to our retina franchise, sura-vec, which is being developed in both wet AMD and diabetic retinopathy with our partner, AbbVie. As we approach top-line data later this quarter, let me review the design of our two pivotal trials, ATMOSPHERE and ASCENT. Together, these trials have enrolled over 1,300 patients across 14 countries and represent the largest gene therapy trials ever conducted. Both trials randomized patients one-to-one-to-one to low-dose sura-vec, high-dose sura-vec, or an on-label anti-VEGF control. The control in ATMOSPHERE is monthly ranibizumab. In ASCENT, the control is aflibercept every eight weeks. The primary endpoint in both studies is non-inferiority on change in best-corrected visual acuity, or BCVA, at 54 weeks. Both studies are powered at 90% with more than 600 patients in each.
In the phase I/II study, at doses similar to those in the pivotal studies, sura-vec-treated patients demonstrated stable to improved visual acuity and had meaningful reductions in anti-VEGF treatment burden through five years. Additionally, sura-vec is the only gene therapy in development to demonstrate the potential to treat both eyes. We believe the ability to target the immune-privileged subretinal space is a significant advantage for patients and physicians and could meaningfully differentiate sura-vec from other investigational gene therapies. We look forward to reporting top-line results by year-end and expect this joint announcement with AbbVie to highlight injection burden and anatomy in addition to the primary endpoint. Turning to diabetic retinopathy, where we continue to advance our pivotal development program. Earlier this year, we dosed the first patient in the phase IIb/III NAAVIGATE study, which triggered a $100 million milestone payment from AbbVie.
More recently, at the Retina Society Annual Meeting, we presented encouraging three-year results from the phase II ALTITUDE trial. The new data highlighted long-term results from dose level 3, the same dose being evaluated in NAAVIGATE. At three years, 60% of patients improved by at least two steps on the diabetic retinopathy severity scale without additional treatment, and three of four patients who improved one step at one year without additional treatment went on to improve by at least two steps by year three. These findings reinforce the potential of sura-vec to change the treatment landscape for the millions of patients with non-proliferative diabetic retinopathy. Turning to RGX-121, we continue to collect and evaluate additional patient imaging and long-term follow-up data with the goal of getting this important treatment to patients.
We are working closely with the FDA and with the support of our partner, NS Pharma, and we will update you on the path forward as we progress. Within the rare disease franchise, our primary focus remains on our potential best-in-class therapy for Duchenne, RGX-202. RGX-202 was designed to maximize potential benefit through the combination of three key elements. One, our novel microdystrophin. The inclusion of the CT domain makes RGX-202 the closest construct to naturally occurring dystrophin. Two, a proactive immune suppression regimen. And three, a commercial-ready manufacturing process that delivers industry-leading product purity. As reported in May, our top-line pivotal results demonstrated robust microdystrophin expression, encouraging functional improvement, and a favorable safety profile. These positive results, together with the statistically significant strong correlation observed between microdystrophin expression and NSAA improvement at one year, will be key components of our upcoming BLA submission.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
